Severe community acquired pneumonia update mortality, mechanisms and medical intervention 英文参考文献.docVIP

Available online /content/12/S6/S1 Introduction Severe community acquired pneumonia update: mortality, mechanisms and medical intervention Pierre-Francois Laterre St Luc University Hospital, Université Catholique de Louvain, Brussels B-1200, Belgium Corresponding author: Pierre-Francois Laterre, laterre@rean.ucl.ac.be Published: 26 November 2008 Critical Care 2008, 12(Suppl 6):S1 (doi:10.1186/cc7024) This article is online at /content/12/S6/S1 ? 2008 BioMed Central Ltd Severe community-acquired pneumonia (CAP) in the inten- sive care unit (ICU) is associated with a high mortality rate of about 30% [1], and this rate has remained largely unaltered since the discovery of antibiotics in the 1950s [2]. Until now, no therapies have been designed specifically as adjunct agents for the treatment of severe CAP. In the majority of cases, broad-spectrum antibiotics or pathogen-directed thera- pies are effective in eradicating the causative organism(s), but they do not address causative effects from pathways of inflammation and coagulation, which are characteristic of the host response to infection. Professor Rello has been actively involved in clinical research for the past 20 years, focusing on the prevention and control of hospital-acquired infections, severe CAP and treatment of infections in critically ill patients. His presentation focused on the epidemiology, diagnosis and severity scoring of severe CAP, and the impact that treatment guidelines have had [5]. Tom van der Poll MD, PhD is Head of the Centre for Experimental and Molecular Medicine in the Academic Medical Centre in Amsterdam. His research is based in the Centre for Infection and Immunity Amsterdam (CINIMA) and focuses on innate immune responses to bacterial and myco- bacterial infection. He also serves on the Steering Committee of the International Sepsis Forum. His prese